ORNL is a leader both in developing advanced radiotherapies and in providing the radioisotopes needed for those therapies.

Good morning, and welcome to KP Tissue's Fourth Quarter 2025 Results Conference Call. Note that today's call is being recorded for replay. [Operator Instructions]. I will now turn the call over to ...

The company expects adjusted EBITDA of approximately breakeven for Q1 2026 due to operational disruptions and higher costs from severe weather, with $15 million to $20 million in incremental costs.

Professor, Aarhus University, Dept. of Biomedicine (West), Director, DANDRITE, Danish Research Institute of Translational Neuroscience, (Nordic EMBL partnership for Molecular Medicine). Co-founder and ...